ESR1 and breast cancer: EMERALD enrolled participants with ER-positive/HER2-negative advanced breast cancer who had received one to two prior lines of endocrine therapy, mandatory pretreatment with a CDK4/6 inhibitor, and no more than one line of chemotherapy.